82 related articles for article (PubMed ID: 6418678)
1. Prevention of experimentally induced gastric damage with the tripeptide ZAMI-420, a new thromboxane synthesis inhibitor.
Gervasi GB; Fossati A; Caliari S; Rapalli L; Bergamaschi M
Int J Tissue React; 1983; 5(3):253-6. PubMed ID: 6418678
[TBL] [Abstract][Full Text] [Related]
2. The tripeptide ZAMI-420 inhibits thromboxane-induced gastric vasoconstriction and ischaemia.
Moroni D; Gervasi GB; Patella P; Visentin L; Maselli MA; Bergamaschi M
Int J Tissue React; 1983; 5(3):249-52. PubMed ID: 6654624
[TBL] [Abstract][Full Text] [Related]
3. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
Mevkh AT; Basevich VV; Varfolomeev SD
Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
[TBL] [Abstract][Full Text] [Related]
4. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
Block HU; Förster W; Heinroth I
Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological studies of imidazole 2-hydroxybenzoate (ITF 182), an antiinflammatory compound with an action on thromboxane A2 production.
Pagella PG; Bellavite O; Agozzino S; Donà GC; Cremonesi P; De Santis F
Arzneimittelforschung; 1983; 33(5):716-26. PubMed ID: 6603228
[No Abstract] [Full Text] [Related]
7. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
[TBL] [Abstract][Full Text] [Related]
8. Increased platelet thromboxane synthesis in diabetes mellitus.
Halushka PV; Rogers RC; Loadholt CB; Colwell JA
J Lab Clin Med; 1981 Jan; 97(1):87-96. PubMed ID: 7452084
[TBL] [Abstract][Full Text] [Related]
9. Reversible inhibition of thromboxane A2 production by imidazole 2-hydroxybenzoate (ITF 182) in the arachidonic acid injected rat. A comparison with acetylsalicylic acid and indometacin.
Pagella PG; Agozzino S; Bellavite O; Donà GC
Arzneimittelforschung; 1984; 34(5):597-8. PubMed ID: 6432000
[TBL] [Abstract][Full Text] [Related]
10. Aggregation and inhibition of rat platelets, and the formation of endoperoxide metabolites.
Hwang DH
Prostaglandins Med; 1980 Sep; 5(3):163-73. PubMed ID: 7413850
[TBL] [Abstract][Full Text] [Related]
11. Effect of an inhibitor of TXA2 synthesis and of PGE2 on the formation of 12-L-hydroxy-5,8,10-heptadecatrienoic acid in human platelets.
Vincent JE; Zijlstra FJ; van Vliet H
Adv Prostaglandin Thromboxane Res; 1980; 6():463-6. PubMed ID: 7386279
[No Abstract] [Full Text] [Related]
12. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of thromboxane A2 biosynthesis in human platelets by burimamide.
Allan G; Eakins KE; Kulkarni PS; Levi R
Br J Pharmacol; 1980; 71(1):157-64. PubMed ID: 6781572
[TBL] [Abstract][Full Text] [Related]
14. Studies of the influence of nitroglycerin on the synthesis of prostaglandins and thromboxane A2 and on platelet aggregation.
Rettkowski W; Pönicke K; Block HU; Giessler C; Dunemann A; Zehl U; Förster W
Arzneimittelforschung; 1982; 32(3):194-200. PubMed ID: 6805480
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin and thromboxane A2 synthesis by rabbit pulmonary artery.
Salzman PM; Salmon JA; Moncada S
J Pharmacol Exp Ther; 1980 Oct; 215(1):240-7. PubMed ID: 7005425
[TBL] [Abstract][Full Text] [Related]
16. [The prostaglandin and thromboxane system of the gastric mucosa as a target for protective and ulcerogenic drugs].
Peskar BM
Wien Klin Wochenschr; 1984 Feb; 96(4):133-8. PubMed ID: 6585091
[TBL] [Abstract][Full Text] [Related]
17. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
Heinroth I; Block HU; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
[TBL] [Abstract][Full Text] [Related]
18. [Thrombocyte interaction with a collagen substrate: the role of thrombocyte-synthesized prostaglandin endoperoxides and thromboxane A2].
Mazurov AB; Leĭtin VL; Repin VS
Biull Eksp Biol Med; 1984 Nov; 98(11):563-6. PubMed ID: 6439262
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway.
Tobias LD; Hamilton JG
Adv Prostaglandin Thromboxane Res; 1980; 6():453-6. PubMed ID: 6770605
[No Abstract] [Full Text] [Related]
20. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
